Global Automated Insulin Delivery System Market 2026 – 2035

The market size of the global automated insulin delivery system will be estimated at USD 989 million in 2025 and is expected to grow between USD 1093 million in 2026 and about USD 2684 million by 2035 with a current CAGR of 10.5% during the period of 2026 to 2035.

The automated insulin delivery system market is basically driven by several factors, including the increasing global incidence of diabetes, especially the cases that are highly reliant on insulin which in turn is creating a long-term market for sophisticated glucose management solutions. With the developments in technology such as boosting of CGM accuracy, insulin pump design and the algorithm-based dosing aided by artificial intelligence and predictive analytics, soon AID systems will be more trusted, easy to use, and clinically effective. Apart from this, the increasing number of patients are getting to know about the diabetes therapy/management; they are also accepting the wearable medical devices, and the whole scenario is changing towards personalized and automated diabetes care hence the adoption rates are getting faster.

The favorable reimbursement policies for the patients in developed healthcare systems, the digital health infrastructure that is getting more and more accessible to the patients, and the research and development that is being done on the fully closed-loop systems are all contributing to the automated insulin delivery system being considered as an essential component in next-generation diabetes management and thus increasing the market for such systems.

Market Highlight

• North America had a market share of 36% and was the market leader in the automated insulin delivery system market in 2025.

• The Asia Pacific is expected to grow at the highest CAGR during the years 2026-2035.

• By product, the Predictive Low Glucose Suspend (PLGS) System segment dominates the market over the forecast period.

• By diabetes type, the Type 1 Diabetes segment is expected to capture the substantial market share over the forecast period.

Significant Growth Factors

The automated insulin delivery system market trends present significant growth opportunities due to several factors:

• Rising Prevalence of Diabetes: The global diabetes epidemic that is on the rise is the major force behind the growth of the automated insulin delivery system market, since the number of people in need of long-term insulin therapy is increasing, which in turn strengthens the demand for glucose management solutions that are advanced. The number of type 1 diabetes patients is gradually increasing, and the type 2 diabetes patients who are insulin-dependent are gradually becoming more and more patients; all these are major factors that the healthcare system has to deal with through the adoption of more accurate, efficient, and user-friendly treatment options. Automated insulin delivery systems are equipped to deal with this demand by providing the patients with the best possible treatment through the continuous checking of glucose levels and real-time insulin dosing adjustment. Diabetes is going to be the major driver of this medical equipment market with the issue of aging people, inactive lifestyles, and unhealthy dietary habits making the already large problem even bigger, thus the market will have no choice but to remain compatible with the existing demand and keep on expanding. For instance, as per the data published by the International Diabetes Federation, 589 million adults (20-79 years) are living with diabetes – 1 in 9. This number is predicted to rise to 853 million by 2050.

• Healthcare Infrastructure and Reimbursement Expansion: The expansion of healthcare infrastructure and reimbursement is essential to the automated insulin delivery system market growth through the patient's easier access to the best technologies available for diabetes management. The investment of developed and yet to be developed healthcare systems in modern hospitals, digital health platforms and specialized diabetes care centers makes the adoption of technology for insulin delivery systems more practical. Moreover, the expansion of both public and private reimbursement policies has greatly diminished the financial burden of insulin pumps, continuous glucose monitoring devices, and integrated AID systems for patients. Insurers and state health programs' coverage encourages both doctors and patients to switch from the traditional insulin therapy to the automated one. The interaction of the healthcare infrastructure improvements with the reimbursement policies not only leads to the penetration of the market but also to the increase of the treatment adherence and the overall growth of the automated insulin delivery systems market being sustained over the long period of time.

What are the Major Advances Changing the Automated Insulin Delivery System Market Today?

• Improved Continuous Glucose Monitoring (CGM) Technology: The enhanced Continuous Glucose Monitoring (CGM) technology is the most significant factor that is altering the automated insulin delivery system market. The modern CGM could give over the classic one very high accuracy, very fast data updates, very long sensor wear times, and improved reliability. This all comes with AID algorithms receiving near-real-time glucose data every few minutes, which enables insulin dose adjustments to become more precise and glucose trends to be predicted better. So, the performance of CGM has been improved, and it has made false alarms less likely, the flows of fast glucose better detected, and the requirements for calibration minimized, these together lighten the user burden and lift the patient's trust in the automated insulin delivering systems. A case in point, the latest CGM sensors are able to continuously send glucose readings to an insulin pump and smartphone application, eventually allowing the AID system to automatically increase the insulin delivery when glucose levels rise or suspend insulin when a downward trend indicates a risk of hypoglycemia. This unobtrusive assistance facilitates the patients staying within the target range of glucose levels for longer periods without manual intervention. The CGM sensors are becoming smaller, more comfortable, and more accurate, which purely increases the safety, effectiveness, and adoption of automated insulin delivery systems, thus driving the market growth indirectly.

• Personalized Predictive Models and Digital Twins: The market for the automated insulin delivery system is one of the earliest adopters of personalized digital twins and predictive models and their distinct advantages. For the prediction of future glucose changes, the sophisticated models capitalize on various technologies, such as AI and machine learning, along with patient-specific data, for example, past glucose levels, insulin efficacy, feeding pattern, exercise, stress, and sleep. Gaining real time metabolic data from the patient through continuous glucose monitoring (CGM) automatically sets up the AID algorithms for the insulin delivery strategy, allowing for selection of the best one. This was possible due to this predictive power, where time-in-range is enhanced, hypoglycemia risk is lowered, and insulin dosing becomes more of a proactive than a reactive process. An example of the AID system outfitted with digital twin technology is the prediction of postprandial glucose levels and the prevention of exercise-induced falls in glucose levels through examination of previous responses in similar situations. The system cannot only sit and watch until glucose levels go up or down, but it can also change the insulin delivery beforehand in order to keep the glucose levels steady. The model will gradually learn the patient's individual physiology and lifestyle and thus become more precise and personalized. The development of these technologies of prediction and virtual modeling in conjunction with their integration into CGM and insulin pump platforms will, it is believed, significantly improve the performance of automation and patient safety and result in the long-term acceptance of advanced automated insulin delivery systems.

Category Wise Insights

By Product

Why Predictive Low Glucose Suspend (PLGS) System Lead the Market?

The Predictive Low Glucose Suspend (PLGS) System segment dominates the market over the forecast period. This is mainly because it prevents users from having to go through the uncomfortable experience of hypoglycemia and at the same time it raises the users' confidence in automated insulin technologies. Predictive low glucose suspend (PLGS) systems are combined with continuous glucose monitoring (CGM) data in real-time and with predictive algorithms to predict the occurrence of hypoglycemia and to automatically stop or reduce the insulin delivery before the glucose levels fall too low, therefore significantly minimizing the incidence of dangerous hypoglycemic events. A feature like this has not only a positive impact on clinical outcomes but also creates the trust of both patients and clinicians in automated insulin solutions, which, in turn, encourages the adoption of AID devices over traditional insulin pumps or manual delivery methods. Research evidence shows that using PLGS-introduced features can significantly shorten the time spent in hypoglycemia, for example, by reducing the time under the low glucose threshold and the number of nocturnal hypoglycemic events.

The Fully Closed Loop (FCL) System segment is expected to grow at the highest CAGR over the projected period. The expansion of this segment can be attributed to the fact that the companies involved are able to provide a more advanced diabetes management solution that is completely automatic in comparison to the earlier hybrid or semi-automatic ones. Fully closed-loop systems make use of continuous glucose monitoring (CGM), insulin pumping, and highly intelligent control algorithms, which work in unison to modify the whole insulin delivery—basal and bolus—so that the user has to intervene only to a small extent. This improved automation not only leads to better glycemic outcomes—like time in the desired range and fewer hypo- and hyperglycemic episodes—but also significantly increases the convenience and quality of life for the user, thus making these systems very attractive for both patients and healthcare providers.

By Diabetes Type

Why Type 1 Diabetes Dominates the Automated Insulin Delivery System Market?

The Type 1 Diabetes segment is expected to capture the substantial market share over the forecast period. The rising trend is attributed to the high and growing prevalence of Type 1 diabetes, which is a disease that requires people to have continuous insulin therapy for their living and satisfactory glucose control. Type 1 diabetes patients need exact and uninterrupted regulation of blood sugar levels and thus, modern technologies like AID systems are given priority for those patients who otherwise have to keep monitoring their glucose levels frequently and doing manual insulin dosing. AID systems are made up of CGM and smart insulin pumps and offer better glycemic outcomes such as more time-in-range and less hypoglycemia which in turn improve one's living standards and the confidence of the clinician in the technology and the patients' trust in it.

The Type 2 Diabetes segment is expected to grow at the highest rate over the projected period. The healthcare professionals' higher understanding of advanced insulin delivery—better glycemic control, hypoglycemia risk reduction, and increased convenience, among others—has been the main cause of AID systems getting more widely recommended, thus facilitating their adoption and sales even more. The clinical awareness of the benefits of AID systems has influenced the market of insulin delivery devices in a wider range, where the Type 2 segment now accounts for a large share that is growing rapidly owing to its size and the increasing need for effective management solutions.

Report Scope

Regional Analysis

How Big is the North America Automated Insulin Delivery System Market Size?

Its market size, in terms of North America automated insulin delivery system, is projected to be USD 356 million in 2025 with a growth of about USD 835 million in 2035 with a CAGR of 8.9% between 2026 and 2035.

Why did North America Dominate the Automated Insulin Delivery System Market in 2025?

In 2025, North America will dominate the global market with an estimated market share of 36%. The expansion in diabetes technologies is mainly influenced by a combination of several factors specific to each region, which together form a very good environment for the advanced technologies. North America—mainly the United States—has a very high number of people with diabetes, which in turn is the reason why the market for machine-operated and integrated insulin delivery solutions that control blood sugar levels more effectively and ease the disease management process is still increasing. The advanced healthcare system of the region, the availability of expert medical personnel, and the high level of patient knowledge about the merits of continuous glucose monitoring (CGM) and automatic systems are some of the reasons why AID technologies are being adopted so widely in this area.

For instance, according to the Diabetes Research Institute Foundation, Diabetes affects 37.3 million individuals, which is equivalent to 11.3% of the U.S. populace. It was considered that 28.7 million persons - had diabetes that was confirmed by a doctor. About 8.6 million individuals have diabetes without being diagnosed so far.

U.S. Automated Insulin Delivery System Market Trends

The automated insulin delivery system market in the U.S. is experiencing sustained revenue growth due to the presence of major players and the growing product approvals. For instance, in December 2025, Insulet Corporation, which has a leading position in the global market for tubeless insulin pump technology with its Omnipod® product line, made an announcement that the FDA has granted it the 510(k) clearance for the Omnipod 5 Automated Insulin Delivery System. The updates to the Omnipod 5 algorithm are giving tubeless diabetes tech a new standard by allowing a lower 100 mg/dL Target Glucose option and a smoother automated experience.

Why is Asia Pacific Experiencing the Fastest Growth in the Automated Insulin Delivery System Market?

Asia Pacific is the main region with the fastest growth in the automated insulin delivery system market. Diabetes is now considered as one of the foremost factors in the demand for AID systems and their related devices. The prevalence of the disease in populous countries such as India and China is on the rise, leading to a large and ever-increasing patient pool that requires proper insulin management solutions.

India Automated Insulin Delivery System Market Trends

The Indian market has an extremely fast-growing market. Healthcare infrastructure has become stronger, advanced devices have become more accessible through urban clinics and private healthcare providers, and diabetes care has been realized through targeted initiatives, all of which are enabling the market to expand their reach. International and domestic companies investing in the distribution and marketing of insulin delivery solutions have also posted great triumphant sales, including pumps with connectivity and smarter algorithms.

Why is Europe is growing at a significant rate in the Automated Insulin Delivery System Market?

Europe holds a significant market share over the projected period. In several European nations, the provision of modern diabetes care technologies is made easier and their acceptance is stimulated by patient and large-scale use through the removal of financial limitations supported by the establishment of favorable healthcare infrastructure, reimbursement programs, and government initiatives. Among other things, Germany, the UK, and France with their solid diabetes care systems are contributing to the expansion of the market.

UK Automated Insulin Delivery System Market Trends

UK holds the dominant position in the Europe market. The Increasing product launches by the market players are expected to flourish the industry growth. For instance, in November 2023, ViCentra B.V., the company behind Kaleido, one of the world's smallest and lightest insulin patch administration devices for type 1 diabetes management, unveiled a Hybrid Closed Loop System for the purpose of insulin delivery automation. The respective system uses the DBLG1 algorithm, which is fed by the Dexcom G6 Continuous Glucose Monitoring (CGM) sensor, to deliver insulin. It merges the comfort of the Kaleido insulin pump with two best-of-breed innovations that have been developed by Diabeloop and Dexcom, respectively, thus producing an easy, flexible and self learning Hybrid Closed Loop System for managing type 1 diabetes.

Why is the Middle East & Africa Region is growing rapidly in the Automated Insulin Delivery System?

The MEA region is growing at a steady rate over the projected period. An increase in healthcare expenditure along with government programs to support diabetes care has made it easier to access the use of the latest technologies for diabetes treatment, and this has resulted in wider use not only in urban but also in rural parts of the region. The collaboration of global medical device companies and local distributors has also led to better availability of products and greater income generation.

UAE Automated Insulin Delivery System Market Trends

UAE is growing at the highest CAGR during the forecast period. The growth is owing to the rising investment in advanced healthcare infrastructure and growing awareness about this sophisticated devices.

Top Players in the Automated Insulin Delivery System Market and Their Offerings

• F. Hoffmann-La Roche Ltd

• Tandem Diabetes Care Inc.

• Insulet Corporation

• Medtronic plc

• Beta Bionics Inc.

• Bigfoot Biomedical Inc.

• Diabeloop SAS

• Ypsomed AG

• Sooil Development Co. Ltd.

• DreaMed Diabetes Ltd.

• Sequel Med Tech LLC

• Abbott

• Medtrum Technologies Inc.

• Dexcom Inc.

• Others

Key Developments

Automated Insulin Delivery System market has experienced considerable changes in the last two years as the market players are trying to diversify their technological aspects and develop product portfolio using strategic approaches.

• In February 2024, Tandem Diabetes Care released the Tandem Mobi insulin delivery system commercially for the US market. Tandem Mobi reportedly is the tiniest, most automated insulin delivery system for diabetes patients in the world. (https://www.medicaldevice-network.com/news/tandem-insulin-system/)

• In January 2026, A real-world retrospective analysis that was recently published in Diabetes Care has demonstrated that the users of the MiniMed™ 780G system were able to meet the American Diabetes Association (ADA) recommended goals for time-in-range (TIR) even on days when mealtime boluses were missed. Data from CareLink™ revealed that the user population under study reached a TIR of 76.3% on bolus-off days when using SmartGuard™ technology with recommended optimal settings (100 mg/dL glucose target; two-hour active insulin time). The research explored off-label user behavior as the system labeling instructs users to declare their meals while using SmartGuard™ technology. Intentionally not injecting insulin is not a prescribed use of the device and is also not recommended. Even though meal announcements are compulsory, this research accentuates the need and significance of optimized settings, especially when some users might have missed the boluses ocassionally. (https://www.prnewswire.com/news-releases/study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-users-forgot-to-bolus-302655231.html)

These strategic measures have enabled the companies to reinforce their competitive positions, increase the product line, boost their technological competencies, and also seize growth opportunities in the fast-growing automated insulin delivery system market.

The Automated Insulin Delivery System Market is segmented as follows:

By Product

• Predictive Low Glucose Suspend (PLGS) System

• Fully Closed Loop (FCL) System

• Hybrid Closed Loop (HCL)/Advanced Hybrid Closed Loop (AHCL) System

By Diabetes Type

• Type 1 Diabetes

• Type 2 Diabetes

By Age Group

• Pediatric

• Geriatric

• Adult

By End User

• Hospitals and Clinics

• Homecare Settings

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America